Last edition
News about Clinical Trials
Eli Lilly's Foundayo and Lower-Dose Zepbound Maintain Weight Loss in Late-Phase Trials
Eli Lilly and Company reports late-stage trial data showing Foundayo and lower-dose Zepbound helped patients maintain significant long-term weight loss after switching from higher-dose incretin therapies.
Clinical Trials | 13/05/2026 | By News Bureau
Ranok Therapeutics Reports Promising Phase 1a Results for KRAS G12D Cancer Therapy RNK08954
Ranok Therapeutics has reported positive Phase 1a clinical data for investigational KRAS G12D inhibitor RNK08954, demonstrating encouraging response rates and tolerability in advanced solid tumor patients, including those with non-small cell lung cancer.
Clinical Trials | 12/05/2026 | By News Bureau | 128
Hengrui Pharma and Braveheart Bio have reported positive Phase 2 clinical trial results for investigational cardiac therapy HRS/BHB-1893 in patients with non-obstructive hypertrophic cardiomyopathy, demonstrating improvements in cardiac function, biomarkers and patient outcomes.
Clinical Trials | 12/05/2026 | By News Bureau | 103
Mabwell Secures FDA Clearance for 9MW5211 Clinical Trial Application
Mabwell receives US Food and Drug Administration (FDA) IND clearance for 9MW5211, a novel antibody therapy being developed for Inflammatory Bowel Disease (IBD) clinical studies.
Clinical Trials | 11/05/2026 | By News Bureau
Bayer Reports Positive Phase 3 Results for Investigational Cardiac Amyloidosis Imaging Agent
REVEAL study demonstrates strong diagnostic sensitivity and specificity of I 124 evuzamitide PET/CT radiotracer for detecting cardiac amyloidosis, supporting plans for regulatory discussions with the FDA.
Clinical Trials | 08/05/2026 | By News Bureau | 112
Samsung Bioepis achieves positive Phase 1 results for Keytruda biosimilar candidate SB27
The biopharmaceutical company announced that its proposed pembrolizumab biosimilar, SB27, met primary pharmacokinetic endpoints in a global Phase 1 study involving non-small cell lung cancer patients, advancing its oncology biosimilar pipeline.
Clinical Trials | 08/05/2026 | By News Bureau | 146
Alebund Pharmaceuticals has completed patient enrollment in its global phase 3 RESPOND-2 study evaluating AP301, a next-generation phosphate binder for CKD patients on dialysis.
Clinical Trials | 07/05/2026 | By News Bureau | 110
JNJ-4804 Co-Antibody Shows Promise in Refractory Inflammatory Bowel Disease
Johnson & Johnson (J&J) investigational JNJ-4804 co-antibody shows superior clinical and endoscopic outcomes in refractory Inflammatory Bowel Disease (IBD), supporting phase 3 advancement with dual IL-23 and TNF pathway targeting.
Clinical Trials | 07/05/2026 | By News Bureau | 112
Anteris Technologies Global Corp. Begins US Enrollment in PARADIGM Trial for DurAVR Heart Valve
Anteris marks first patients successfully treated in US as global trial evaluates safety and effectiveness of DurAVR THV against existing transcatheter aortic valve therapies.
Clinical Trials | 06/05/2026 | By News Bureau
Altesa BioSciences Initiates Phase IIb CARDINAL Trial for COPD Treatment
Altesa BioSciences begins global CARDINAL trial to assess antiviral vapendavir for improving symptoms and lung function in COPD patients.
Clinical Trials | 06/05/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy